Leiden University Scholarly Publications

Search results

  • RSS Feed
(1 - 4 of 4)
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Primary Granulocyte Colony-Stimulating Factor Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Patients With Breast Cancer at Risk for Febrile Neutropenia
Cost Effectiveness of Primary Pegfilgrastim Prophylaxis in Patients With Breast Cancer at Risk of Febrile Neutropenia
COST-EFFECTIVENESS OF PRIMARY PEGFILGRASTIM PROPHYLAXIS IN BREAST CANCER PATIENTS AT RISK OF FEBRILE NEUTROPENIA